Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» amivantamab
amivantamab
J&J beats Tagrisso and Takeda to the punch in key NSCLC subset, picking up new FDA approval
Endpoints
Sun, 05/23/21 - 03:08 pm
JNJ
non-small cell lung cancer
Janssen
amivantamab
FDA
#ASCO21: J&J busts out a small update for its antibody-TKI combo in lung cancer — whetting appetites as FDA thinks it over
Endpoints
Thu, 05/20/21 - 12:21 pm
ASCO 2021
JNJ
amivantamab
non-small cell lung cancer
JNJ's amivantamab puts more data behind the hype
EP Vantage
Tue, 02/2/21 - 11:11 pm
JNJ
amivantamab
exon 20-insertion NSCLC
J&J pushes new amivantamab data for NSCLC subset, trying to bolster case for quick FDA approval
Endpoints
Thu, 01/28/21 - 11:16 pm
JNJ
amivantamab
non-small cell lung cancer
Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication
Endpoints
Mon, 12/21/20 - 10:59 am
AstraZeneca
Tagrisso
non-small cell lung cancer
JNJ
amivantamab
In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA
Fierce Biotech
Thu, 12/3/20 - 10:55 am
Janssen
non-small cell lung cancer
FDA
amivantamab
JNJ
metastatic non-small cell lung cancer